AUY922 + BYL719

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Conditions

Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Trial Timeline

Dec 1, 2012 → Mar 1, 2014

NCT ID

NCT01613950

About AUY922 + BYL719

AUY922 + BYL719 is a phase 1 stage product being developed by Novartis for Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein. The current trial status is completed. This product is registered under clinical trial identifier NCT01613950. Target conditions include Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein.

What happened to similar drugs?

1 of 8 similar drugs in Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein were approved

Approved (1) Terminated (1) Active (6)

✅E0671 + rabeprazole sodium + E0671 placeboEisaiApproved

🔄epoetin alfaJohnson & JohnsonPhase 3

🔄Pembrolizumab + Cisplatin + 5-fluorouracil + oxaliplatin + capecitabine + Placebo for PembrolizumabMerckPhase 3

🔄Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + CapecitabineMerckPhase 3

❌Pembrolizumab + Cisplatin + 5-fluorouracil + Oxaliplatin + Capecitabine + Placebo for PembrolizumabMerckPhase 3

🔄ECC + FOLFIRIRochePhase 3

🔄Capecitabine + OxaliplatinRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01613950	Phase 1	Completed	Dec 1, 2012	Mar 1, 2014	Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Competing Products

20 competing products in Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

See all competitors

Product	Company	Stage	Hype Score
EO-3021 + Ramucirumab (CYRAMZA®) + Dostarlimab	CSPC Pharmaceutical Group Limited	Phase 1	21
E0671 + rabeprazole sodium + E0671 placebo	Eisai	Approved	43
Pariet	Eisai	Pre-clinical	26
Ramucirumab + Placebo + Oxaliplatin + Leucovorin + 5-Fluorouracil	Eli Lilly	Phase 2	35
Ramucirumab + Capecitabine + Cisplatin + S-1 + Oxaliplatin	Eli Lilly	Phase 1	29
Ramucirumab + Paclitaxel	Eli Lilly	Phase 2	39
epoetin alfa	Johnson & Johnson	Phase 3	40
MK0782	Merck	Phase 2	35
Pembrolizumab + Cisplatin + 5-fluorouracil + oxaliplatin + capecitabine + Placebo for Pembrolizumab	Merck	Phase 3	40
Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine	Merck	Phase 3	40
Pembrolizumab + Cisplatin + 5-fluorouracil + Oxaliplatin + Capecitabine + Placebo for Pembrolizumab	Merck	Phase 3	32
ECC + FOLFIRI	Roche	Phase 3	40
Capecitabine + Oxaliplatin	Roche	Phase 3	40
Atezolizumab + Capecitabine + Oxaliplatin + Docetaxel	Roche	Phase 2	39
Atezolizumab + Tiragolumab + Oxaliplatin + Capecitabine	Roche	Phase 2	27
Epirubicin, Cisplatin, Capecitabine, Panitumumab + Epirubicin, Cisplatin, Capecitabine	Amgen	Phase 2	35
AMG 337	Amgen	Phase 1/2	32
AMG 337	Amgen	Phase 2	27
Cisplatin + S-1 + Sunitinib	Pfizer	Phase 1	29
axitinib + capecitabine + cisplatin	Pfizer	Phase 1	29